Click the title above for a link to open the Pharmaceutical Executive February 2025 issue in an interactive PDF format.
Pharmaceutical Executive: February 2025
Welcome to a bold new look for Pharmaceutical Executive's print and digital magazine.
Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic areas.
How one Big Pharma ad campaign is incorporating diversity as a driving force in improving the ways drugs are marketed directly to the patients that need them.
The benefits for brand teams in bolstering their rapid-response capability.
Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.
Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.
A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and biotech ahead.
Demonstrating clinical benefit is the ultimate gateway to smoother patient access.
The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.
The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.
